



## Efficacy Study Summary of the D6 STERIONIZER™ against aerosolized SARS-CoV-2

<b>Project</b>	Filt Air Ltd. D6 Sterionizer™ Aerosol SARS-CoV-2
<b>Product</b>	D6 STERIONIZER™ BIPOLAR NEEDLEPOINT IONIZER
<b>Laboratory Project #</b>	1047
<b>Testing Facility</b>	Innovative Bioanalysis, Inc
<b>Study Dates</b>	04/12/2021 – 08/03/2021
<b>GLP Compliance</b>	All internal SOPs and processes follow GCLP guidelines and recommendations.
<b>Test Substance</b>	SARS-CoV-2 USA-CA1/2020
<b>Description</b>	Filt Air Ltd. provided a D6 STERIONIZER™, a compact bipolar needlepoint-ionizing device designed to be integrated into an air movement system such as an HVAC duct system, air conditioner or humidifier. The in vitro study evaluates the efficacy of the D6 STERIONIZER™ against aerosolized SARS-CoV-2.
<b>Test Conditions</b>	The study conducted two control tests and 3 viral challenges in a certified Biosafety hood inside a BSL-3 laboratory. The temperature during testing was approximately 73 ±2°F, with a relative humidity of 44%. Air samples were collected after 0, 15 and 30-minute exposure to the operating device.
<b>Test Results</b>	Active SARS-CoV-2 concentrations were observed to have been significantly reduced at the 15-minute and 30-minute time point. After 15 minutes of operation, the trial observed a decrease in the initial viral concentration of 7.02 x 10 <sup>6</sup> to an average of 2.97 x 10 <sup>6</sup> TCID50/ml and after 30 minutes to an average of 8.86 x 10 <sup>4</sup> TCID50/ml.

<i>Exposure Time</i>	<i>Reduction in %</i>
15 minutes	57.71
30 minutes	98.74

<b>Conclusion</b>	The Filt Air Ltd. D6 STERIONIZER™ demonstrated the ability to reduce the concentration of aerosolized SARS-CoV-2 when exposed to a negative and positive ion concentration.
-------------------	---

DocuSigned by:

Kevin Noble

5DF2797BAA78421...

9/7/2021

Kevin Noble  
Laboratory Director, Innovative Bioanalysis, Inc.

Date